On April 27, 2018, Paul R. Edick resigned from the Board of Directors of Neos Therapeutics, Inc. Mr. Edick resigned to focus on other professional opportunities and his decision to resign from the Board was not the result of any disagreement with the company on any matter relating to the company's operations, policies or practices. On April 27, 2018, the Board unanimously appointed Linda M. Szyper to the Board to fill the resulting vacancy. Upon her appointment to the Board, Ms. Szyper became a member of the class of directors with terms expiring at the 2018 Annual Meeting of Stockholders of the company. The Board has determined that Ms. Szyper qualifies as an independent director and is qualified to serve under the applicable rules and regulations of the Securities and Exchange Commission (the SEC) and the listing rules of the Nasdaq Stock Market LLC. Ms. Syzper will serve as a member of the company's Compensation Committee and Nominating and Corporate Governance Committee. Ms. Szyper has also entered into the company's standard form of indemnification agreement. Ms. Szyper has been the Chief Operating Officer at McCann Health since January 2018. From September 2014 to March 2017, Ms. Szyper was the Chief Commercial Officer and President, US Operations at Circassa Pharmaceuticals plc, or Circassa. Prior to joining Circassa, Ms. Szyper was the Chief Development Officer, PHCG Global Development of Publicis Healthcare Group from January 2008 to September 2014.